Gilead is dealing with more turbulence in its development of CD47-targeting antibody magrolimab, with a partial clinical hold placed on the drug by the FDA in acute myeloi
Gilead Sciences has put $66 million down to start a collaboration with San Diego start-up Tentarix Biotherapeutics to develop new therapeutics for cancer and inflammatory
Arcus and Gilead Sciences have decided not to continue the development of their A2 receptor antagonist etrumadenant in castration-resistant prostate cancer (CRPC) after an
When ViiV Healthcare and Johnson & Johnson launched their once-monthly injectable HIV treatment Cabenuva in 2021, they predicted that patients would prefer that option
Gilead Sciences has said it will stop the development of its cancer antibody magrolimab in blood cancer myelodysplastic syndromes (MDS) after disappointing results in a ph
AstraZeneca and partner Daiichi Sankyo have their first phase 3 data for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) – in lung cancer –